tiprankstipranks
Trending News
More News >
Indaptus Therapeutics (INDP)
NASDAQ:INDP
US Market
Advertisement

Indaptus Therapeutics (INDP) AI Stock Analysis

Compare
535 Followers

Top Page

INDP

Indaptus Therapeutics

(NASDAQ:INDP)

Rating:27Underperform
Price Target:
Indaptus Therapeutics is facing considerable financial and operational difficulties, as highlighted by its poor financial performance with no revenue and continuous losses. The technical analysis further supports a negative outlook, with indicators pointing to bearish momentum. The company's valuation is unattractive due to its unprofitability and lack of dividends. Collectively, these factors suggest a high-risk investment with limited short-term upside potential.
Positive Factors
Clinical Development
The combination study of Decoy and tislelizumab is ongoing, with positive safety results so far, which is promising for the treatment of solid tumors.
Safety Profile
Multiple doses of Decoy20 have shown to be safe and well-tolerated in over 25 patients, indicating a promising safety profile for the therapy.
Strategic Partnerships
Indaptus signed a clinical supply agreement with BeiGene for its PD-1, tislelizumab, which could enhance the study by potentially combining treatments.
Negative Factors
Capital Requirements
Indaptus will need to raise additional capital to continue the clinical development of its Decoy immune therapy.
Financial Concerns
The price target for Indaptus stock has been lowered due to expected dilution from future capital raises and recent financing activities.
Financial Health
Indaptus reported a net loss of ($4.5M) and ended the period with $3.9M in cash on the balance sheet.

Indaptus Therapeutics (INDP) vs. SPDR S&P 500 ETF (SPY)

Indaptus Therapeutics Business Overview & Revenue Model

Company DescriptionIndaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
How the Company Makes MoneyIndaptus Therapeutics primarily makes money through the development and potential commercialization of its therapeutic candidates. The company's revenue model is centered around advancing its drug candidates through clinical trials, obtaining regulatory approvals, and eventually bringing these drugs to market. Key revenue streams include potential milestone payments and royalties from licensing agreements and strategic partnerships with larger pharmaceutical companies. These collaborations may provide funding for research and development activities, as well as access to distribution networks upon successful drug commercialization. Additionally, Indaptus may seek to secure grants and funding from governmental and non-governmental organizations to support its research initiatives.

Indaptus Therapeutics Financial Statement Overview

Summary
Indaptus Therapeutics faces significant financial challenges, with no revenue generation and consistent net losses impacting its income statement. The balance sheet shows declining equity and negative returns, reflecting financial instability. Cash flow statements indicate liquidity issues, as the company struggles to generate positive cash flow. These factors collectively highlight a high-risk financial position for the company.
Income Statement
10
Very Negative
Indaptus Therapeutics has consistently reported zero revenue over the years, which is a major concern for financial health. The company has also experienced significant net losses each year, with no gross profit margins to report. The negative EBIT and EBITDA margins indicate ongoing operational challenges, and the lack of revenue growth further reflects its struggles in generating income.
Balance Sheet
25
Negative
The balance sheet reveals a relatively low level of debt, as evidenced by a low debt-to-equity ratio. However, the company's equity has been decreasing over the years, reflecting financial instability. The return on equity is negative, driven by persistent net losses, which is a major drawback. The equity ratio remains positive but has been declining, showing a weakening financial position.
Cash Flow
15
Very Negative
Cash flow analysis shows a consistent trend of negative free cash flow, indicating that the company is not generating sufficient cash to cover its operational needs. The operating cash flow to net income ratio is negative, further highlighting cash management issues. Despite occasional inflows from financing activities, the company's cash position has been declining, posing liquidity risks.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.47K0.000.000.000.000.00
Gross Profit0.00-735.00-1.28K-1.78K-1.40K-852.00
EBITDA-17.12M-15.02M-16.38M-14.91M-7.73M-3.60M
Net Income-16.96M-15.02M-15.42M-14.32M-7.69M-3.57M
Balance Sheet
Total Assets6.84M7.34M14.92M28.06M40.58M1.78M
Cash, Cash Equivalents and Short-Term Investments6.16M5.79M13.36M26.43M39.13M1.64M
Total Debt34.37K84.16K175.05K80.49K169.33K0.00
Total Liabilities8.51M3.39M2.85M3.43M4.68M2.02M
Stockholders Equity-1.67M3.94M12.08M24.63M35.90M-237.70K
Cash Flow
Free Cash Flow-14.97M-12.32M-13.41M-13.25M-11.29M-3.32M
Operating Cash Flow-14.97M-12.32M-13.41M-13.08M-11.29M-3.32M
Investing Cash Flow0.000.0017.14M-16.43M447.75K0.00
Financing Cash Flow13.83M4.75M0.000.0048.34M1.16M

Indaptus Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price7.35
Price Trends
50DMA
9.73
Negative
100DMA
10.84
Negative
200DMA
18.05
Negative
Market Momentum
MACD
-0.74
Negative
RSI
40.90
Neutral
STOCH
25.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INDP, the sentiment is Negative. The current price of 7.35 is below the 20-day moving average (MA) of 7.85, below the 50-day MA of 9.73, and below the 200-day MA of 18.05, indicating a bearish trend. The MACD of -0.74 indicates Negative momentum. The RSI at 40.90 is Neutral, neither overbought nor oversold. The STOCH value of 25.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INDP.

Indaptus Therapeutics Risk Analysis

Indaptus Therapeutics disclosed 56 risk factors in its most recent earnings report. Indaptus Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Indaptus Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
HK$19.22B4.48-1.43%3.30%11.19%-15.58%
45
Neutral
$6.62M-188.48%69.35%
45
Neutral
$4.92M-107.45%79.38%
43
Neutral
$4.35M-51.83%-2.94%34.52%
34
Underperform
$6.52M-82.72%-100.00%54.46%
27
Underperform
$7.92M-755.04%28.04%
$4.53M
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
INDP
Indaptus Therapeutics
7.35
-38.01
-83.80%
PALI
Palisade Bio
0.75
-2.69
-78.20%
TCRT
Alaunos Therapeutics
1.77
-1.42
-44.51%
TTNP
Titan Pharmaceuticals
4.99
-1.41
-22.03%
XBIO
Xenetic Biosciences
3.03
-1.12
-26.99%
XAGE
Longevity Health Holdings
2.61
-18.58
-87.68%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 21, 2025